Dyax (DYAX) Said Study Shows DX-88 Provides Rapid and Sustained Relief for Hereditary Angioedema
More News related to DYAX
- DX-88 (ecallantide) Demonstrated Relief of Symptoms in Hereditary Angioedema Acute Attacks in All Attack Locations
- National Securities Initiates Coverage on Dyax (DYAX) with a Buy
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Dyax Corp. (DYAX) Posts Q3 Loss of $0.17, Wider Than Expected
- Dyax Corp. Announces Third Quarter 2009 Financial Results
Dyax Corp. (Nasdaq: DYAX) announced presentation of an integrated analysis of the two DX-88 Phase 3 studies demonstrating that treatment with DX-88 (ecallantide) provided clinically meaningful, rapid and sustained relief of symptoms in acute attacks of hereditary angioedema (HAE), when compared to placebo.
Statistically significant improvement in symptoms was demonstrated with DX-88 at four hours after treatment and persisted throughout the 24-hour period of evaluation. The integrated analysis also demonstrated that DX-88 was efficacious in treating all acute attack locations (laryngeal, abdominal, peripheral) and was well tolerated, with no treatment-related serious adverse events.
More from Release
Related Categories
FDAStocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
